An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
As the biotech markets turned bullish the sector’s ups and downs continued.
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
Imbruvica faces challenges on multiple fronts.
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.